Tax cuts are great, right? Not always, as Medical Developments — maker of the famous Aussie “green whistle” pain reliever — pointed out in its 2018 results today.
MedDev’s Penthrox product — often referred to as the “green whistle” — is a self-administered non-opioid pain relief inhaler used in trauma settings.
Today MedDev reported its full-year profit had plunged 87 per cent to $243,000 — and the reason they gave was a tax cut, from 30 per cent to 27.5 per cent.
The tax change meant they had to lower the value of a deferred tax asset and add a $107,000 charge to their expenses.
MedDev (ASX:MVP) also reported a 17 per cent rise in expenses and a drop in revenue of 5 per cent to $17.9 million.
The company blamed higher expenses on rising ‘pharmacovigilance’ costs as they push their non-opioid painkiller Penthrox into new countries and higher marketing and distribution expenses.
‘Pharmacovigilance’ is the extra monitoring of drugs after they have been licensed particularly to identify and previously unreported adverse reactions.
MVP said delays in getting Penthrox approved in 23 European countries until the end of 2018 meant sales have been pushed into 2019.
Get the latest Stockhead news delivered free to your inbox
For investors, getting access to the right information is critical.
Stockhead’s daily newsletters make things simple: Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
It’s free. Unsubscribe anytime.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.
I want the news:
Hear it first
Get the latest Stockhead news delivered free to your inbox.
Thanks! You’re subscribed, Stockhead news is coming your way soon.